Biomarkers in veterinary cancer screening: Applications, limitations and expectations.

The identification of biomarkers that distinguish diseased from normal individuals is of intense interest in many health-related fields. Potential applications for biomarkers in veterinary oncology include diagnosis, staging, prognosis and monitoring responses to therapy. By definition, effective biomarkers for cancer screening facilitate disease identification in sub-clinically affected patients and lead to subsequent improvements in clinical outcome. Although the methods and techniques of biomarker discovery and clinical application are translatable from humans to animals, veterinary medicine has lagged behind its human counterpart in several areas. Veterinarians have previously had a flawed understanding of how to use biomarker assays appropriately and have not had the positive influence on product research and development that could advance this field. The controversies, potentials biases, and considerations relative to the clinical application of biomarker assays for cancer screening are discussed in this review.

[1]  D. Borjesson,et al.  Detection of canine transitional cell carcinoma using a bladder tumor antigen urine dipstick test. , 1999, Veterinary clinical pathology.

[2]  E. Winer,et al.  On mammography--more agreement than disagreement. , 2009, The New England journal of medicine.

[3]  J. Cerón,et al.  Preliminary studies of serum acute-phase protein concentrations in hematologic and neoplastic diseases of the dog. , 2005, Journal of veterinary internal medicine.

[4]  J. Phang,et al.  Prolidase in human breast cancer MCF-7 cells. , 1998, Cancer letters.

[5]  S. Eriksson,et al.  A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. , 2006, Research in veterinary science.

[6]  G. Ball,et al.  Serum biomarker profiling in cancer studies: a question of standardisation? , 2008, Veterinary and comparative oncology.

[7]  G. Ogilvie,et al.  Concentration of alpha 1-acid glycoprotein in dogs with malignant neoplasia. , 1993, Journal of the American Veterinary Medical Association.

[8]  F. Shofer,et al.  Canine intracranial primary neoplasia: 173 cases (1986-2003). , 2006, Journal of veterinary internal medicine.

[9]  M. Karayannopoulou,et al.  Total serum alkaline phosphatase activity in dogs with mammary neoplasms: a prospective study on 79 natural cases. , 2003, Journal of veterinary medicine. A, Physiology, pathology, clinical medicine.

[10]  C. Lamb.  Statistical briefing--sensitivity and specificity. , 2007, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[11]  S. Lucas,et al.  Serum amyloid A is not a marker for relapse of multicentric lymphoma in dogs. , 2008, Veterinary clinical pathology.

[12]  P. Eckersall,et al.  Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. , 2007, Veterinary journal.

[13]  R. Beynon,et al.  Proteomics and naturally occurring animal diseases: Opportunities for animal and human medicine , 2008, Proteomics. Clinical applications.

[14]  Brian Mooney,et al.  Proteomics of Canine Lymphoma Identifies Potential Cancer-Specific Protein Markers , 2007, Clinical Cancer Research.

[15]  B. Kramer,et al.  Cancer screening in theory and in practice. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[17]  L. Hansson,et al.  Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay. , 2009, International journal of oncology.

[18]  K P Freeman,et al.  Serum alpha 1-acid glycoprotein concentrations before and after relapse in dogs with lymphoma treated with doxorubicin. , 1999, Journal of the American Veterinary Medical Association.

[19]  C. Lamb.  Statistical briefing: SpPInS and SnNOuts. , 2007, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[20]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[21]  P. Morley,et al.  Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma. , 2006, Journal of veterinary internal medicine.

[22]  Alexandre Merlo,et al.  Serum C-reactive protein concentrations in dogs with multicentric lymphoma undergoing chemotherapy. , 2007, Journal of the American Veterinary Medical Association.

[23]  G. Borst,et al.  Comparison of clinical and pathological diagnoses in dogs , 2005, The Veterinary quarterly.

[24]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[25]  L. Marconato,et al.  Serum lactate dehydrogenase activity in canine malignancies. , 2009, Veterinary and comparative oncology.

[26]  D. McCaw,et al.  Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. , 2003, American journal of veterinary research.

[27]  W. Spillman,et al.  Canine cancer screening via ultraviolet absorbance and fluorescence spectroscopy of serum proteins. , 2007, Applied optics.

[28]  Scott J Walmsley,et al.  Identification of serum biomarkers for canine B-cell lymphoma by use of surface-enhanced laser desorption-ionization time-of-flight mass spectrometry. , 2007, American journal of veterinary research.

[29]  H. Nelson,et al.  Screening for Breast Cancer: An Update for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.

[30]  E. Karna,et al.  Prolidase activity disregulation in chronic pancreatitis and pancreatic cancer. , 2002, Hepato-gastroenterology.

[31]  A. Hasegawa,et al.  Plasma thymidine kinase activity in dogs with lymphoma and leukemia. , 1997, The Journal of veterinary medical science.

[32]  A. Mobasheri,et al.  Proteomic identification and profiling of canine lymphoma patients. , 2009, Veterinary and comparative oncology.